PubMed Health⌕ Search

Biomedical subjects

E Quellhorst

Publications and source records attributed to E Quellhorst.

At least 19 recordsLinked to original sources
PubMed1991

Fluid balance during haemodialysis and haemofiltration: the effect of dialysate sodium and a variable ultrafiltration rate.

One of the main causes of hypotension during extracorporeal renal replacement therapy is an insufficient substitution of the ultrafiltrated plasma water by tissue water. To investigate the fluid balance and its effects on hypotension in dialysed patients, the following variables were studied: intracellular fluid volume (IFV) and extracellular fluid volume (EFV), blood volume (BV) and blood pressure. IFV and EFV were measured by means of non-invasive electrical conductivity measurements using four electrodes round the leg. Fifteen haemofiltration (HF) and 15 haemodialysis (HD) patients were studied. The latter group was dialysed in three ways: (1) conventionally, i.e. with dialysate sodium of 138 mmol/l (HD) (2) with a variable dialysate sodium (first half: 138 mmol/l; second half: 146 mmol/l) (HDS), and (3) with the same variable dialysate sodium and an ultrafiltration profile (two-thirds was withdrawn during the first half of treatment, the remainder during the second half) (HDSU). Hypotension frequency was less during HDS, HDSU, and HF compared to HD. This was caused by a more stable blood volume due to a better refill. During HD a fluid shift occurred from the EC to the IC compartment. The use of a high sodium dialysate concentration led to a transcellular fluid shift in the opposite direction. This fluid shift increased the refill, thereby stabilising blood volume. HF gave a better refill than HDS and HDSU, probably due to a reduced urea clearance.

Aged↗
PubMed1988

[Determination of the diameter of erythrocytes in the urine in urologic diseases and so-called asymptomatic microhematuria].

In a blind-study with 96 patients analysis of erythrocyte diameters permits to differentiate between renal-parenchymatous and post-renal microhaematuria in 89.9% of the cases. Erythrocytes on renal-parenchymatous microhaematuria are distinctly smaller (Average diameter 3.2 microns-5.6 microns) than those on post-renal microhaematuria (average diameter 5.4 microns-8.8 microns). In addition to the evaluation of erythrocyte morphology erythrocyte morphometry represents further possibility in diagnosis.

Adolescent↗
PubMed1985

Low molecular weight heparin in hemodialysis and hemofiltration patients.

Low molecular weight (LMW)-heparin was used as the sole anticoagulant during hemodialysis and hemofiltration in a pilot study on 32 patients. A LMW-heparin dose corresponding to 50% of the patients usual unfractionated, standard (UF)-heparin dose was found to produce comparable plasma heparin levels (anti-FXa-activity). No thrombosis of the extracorporal system and no bleeding complications occurred at this LMW-heparin dose. In contrast to UF-heparin, LMW-heparin produced only slight increases in PTT and thrombin time in all patients. Lipoprotein lipase was stimulated only marginally by LMW-heparin, with a correspondingly reduced release of free fatty acids. Both heparin species caused similar elevations in factor VIII and fibrin monomers, thus excluding a difference in coagulation activation. On the basis of these results, long-term studies have been started at four nephrology centers. To date, 26 patients have been treated with LMW-heparin for 6 months. A LMW-heparin dose was used that produced plasma anti-FXa-activity of 0.5 to 0.9 U/ml (initial dose: 30 to 40; dose/hr: 8 to 15 anti-FXa-units/kg body wt). PTT and thrombin time were only increased by 5 sec on average. Surprisingly, the elevated pre-dialysis levels of factor VIII and fibrin monomers decreased during this 6-month period. Bleeding complications did not occur and thrombotic complications were not observed when the anti-FXa levels were above 0.5 U/ml. LMW-heparin, therefore, appears to be a good alternative to UF-heparin for dialysis patients and may present less risk of bleeding because of its reduced effect on PTT, thrombin time, and thrombocytes.

Blood↗